- Home
- CLLS vs VXRT Comparison
CLLS vs VXRT Comparison
Compare CLLS & VXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- VXRT
- Stock Information
- Founded
- CLLS 1999
- VXRT N/A
- Country
- CLLS France
- VXRT United States
- Employees
- CLLS N/A
- VXRT N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLLS Health Care
- VXRT Health Care
- Exchange
- CLLS Nasdaq
- VXRT Nasdaq
- Market Cap
- CLLS 148.1M
- VXRT 170.2M
- IPO Year
- CLLS 2007
- VXRT N/A
- Fundamental
- Price
- CLLS $1.53
- VXRT $0.71
- Analyst Decision
- CLLS Buy
- VXRT Buy
- Analyst Count
- CLLS 3
- VXRT 1
- Target Price
- CLLS $7.00
- VXRT $4.00
- AVG Volume (30 Days)
- CLLS 114.3K
- VXRT 1.2M
- Earning Date
- CLLS 11-04-2024
- VXRT 03-13-2025
- Dividend Yield
- CLLS N/A
- VXRT N/A
- EPS Growth
- CLLS N/A
- VXRT N/A
- EPS
- CLLS N/A
- VXRT N/A
- Revenue
- CLLS $36,042,000.00
- VXRT $16,760,000.00
- Revenue This Year
- CLLS $387.77
- VXRT $128.77
- Revenue Next Year
- CLLS $11.14
- VXRT N/A
- P/E Ratio
- CLLS N/A
- VXRT N/A
- Revenue Growth
- CLLS 46.96
- VXRT 303.27
- 52 Week Low
- CLLS $1.41
- VXRT $0.52
- 52 Week High
- CLLS $3.38
- VXRT $1.43
- Technical
- Relative Strength Index (RSI)
- CLLS 45.06
- VXRT 48.01
- Support Level
- CLLS $1.51
- VXRT $0.68
- Resistance Level
- CLLS $1.62
- VXRT $0.78
- Average True Range (ATR)
- CLLS 0.09
- VXRT 0.05
- MACD
- CLLS 0.01
- VXRT -0.00
- Stochastic Oscillator
- CLLS 29.17
- VXRT 48.85
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.